Together, our data and pre-clinical and clinical findings indicate that a combination strategy of HSP90 inhibitors with HER2-targeted agents may have more clinical benefits in patients with ER (+) HER2 (+) subtype breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.